Gene variant increases breast cancer risk

Mar 14, 2008

In roughly five to ten percent of breast cancer cases there is a family history of breast cancer– i.e., hereditary and, thus, genetic factors play a role here. Alterations in the genes known as BRCAI and BRCAII are a major cause of familial breast cancer – these are responsible for roughly 25 percent of such cases.

“In Germany, 75 percent of familial breast cancers are not attributable to mutations in BRCAI and BRCAII. We assume that these cancers are caused in part by rare mutations and in part by unfavorable combinations of risk variants in various genes, which, on their own, have only little effect. Only very few of these have been identified so far – we are searching for the other ones,” said Associate Professor Dr. Barbara Burwinkel of the DKFZ.

Members of the AKAP protein family are responsible for transmitting important signals in a cell. Scientists have suspected these proteins to be involved in cancer development. A large international study headed by Barbara Burwinkel has now delivered proof that this is true for breast cancer.

In collaboration with the German Consortium for Familial Breast and Ovarian Cancers, the research team studied six gene variants in the AKAP family. Two of these, both located on the AKAP9 gene, have indeed been found to be associated with an increased breast cancer risk. Since the two gene variants are always inherited together, further investigations will have to determine whether one of these or both variants in combination are responsible for the risk effect. This finding was confirmed by a large international study in collaboration with researchers from Germany, the United Kingdom, the U.S.A. and Australia. The study included 9,523 breast cancer patients including 2,795 familial breast cancer cases and almost 14,000 healthy women.

For women carrying the two variants in both copies of their AKAP9 genes, the risk of developing breast cancer in the course of their lifetimes is elevated by 17 percent. In women from breast cancer families, this effect is even more substantial: their risk is increased by 27 percent. If only one of the AKAP9 copies is affected, the breast cancer risk is only slightly elevated by approximately eight percent or twelve percent for women from breast cancer families, respectively.

“This shows that the AKAP9 variants have much less effect on breast cancer risk than, for example, BRCA mutations. On the other hand, these variants are much more common in the population. We also do not know yet which control cycles of the cell metabolism are affected and how this can lead to cancer,” said Barbara Burwinkel to qualify the finding. “But there is already evidence suggesting that the two variants also increase the risk of developing lung cancer or colon cancer.”

Source: Helmholtz Association of German Research Centres

Explore further: Clumped cancer cells spread more efficiently through the body than lone ones

add to favorites email to friend print save as pdf

Related Stories

Mayo collaboration finds source of breast drug side effect

Sep 27, 2010

Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

49 minutes ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

4 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

5 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.